An initial public offering of over 1.1 million shares on the Nasdaq Capital Market pulled in $7.1 million in gross proceeds for Co-Diagnostics. Net proceeds will be used as working capital, as well as to support test development, in-field test performance assessment and validation, regulatory submissions for diagnostic tests, laboratory facilities expansion and general corporate functions.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.